4,545 Shares of Danaher Corporation $DHR Acquired by Seelaus Asset Management LLC

Seelaus Asset Management LLC acquired a new stake in Danaher Corporation (NYSE:DHR) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 4,545 shares of the conglomerate’s stock, valued at approximately $1,007,000.

A number of other large investors also recently bought and sold shares of DHR. BlackRock Inc. bought a new stake in shares of Danaher in the 2nd quarter valued at approximately $10,492,520,000. Wellington Management Group LLP lifted its stake in Danaher by 10.4% during the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after purchasing an additional 1,542,310 shares during the last quarter. Jupiter Topco LLC bought a new position in Danaher during the second quarter worth $1,456,317,000. Generation Investment Management LLP bought a new position in Danaher during the second quarter worth $1,287,949,000. Finally, Bank of America Corp DE acquired a new position in Danaher in the second quarter worth $993,846,000. Institutional investors own 79.05% of the company’s stock.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a favorable combination of earnings-estimate revisions and its Earnings ESP, suggesting the company could exceed consensus expectations in its upcoming report. This is supporting optimism ahead of results. Danaher Earnings Expected to Grow
• Positive Sentiment: NVIDIA AI partnership: Danaher announced a collaboration with NVIDIA to combine its scientific instruments, automation systems, laboratory workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative could improve laboratory productivity and strengthen Danaher’s long-term growth prospects. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous-lab opportunity: Danaher plans to launch its first AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027. Although the initial market reaction was limited, the move gives investors another potential growth avenue in life-science automation and AI-driven drug discovery. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support and board changes: Morgan Stanley maintained its $240 price target, while Danaher expanded its board to 13 members with the appointments of Daniel Comas and Robert Hershberg. These developments provide stability but are not expected to materially change near-term earnings. Morgan Stanley Maintains Danaher Price Target
• Neutral Sentiment: Upcoming earnings focus: Investors are monitoring the company’s projected earnings announcement, with expectations for earnings growth likely to keep attention on execution and forward guidance. Danaher Projected Earnings Announcement

Danaher Stock Performance

NYSE:DHR traded up $1.63 during midday trading on Wednesday, reaching $224.47. 1,984,723 shares of the company traded hands, compared to its average volume of 4,449,140. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The firm has a market capitalization of $157.80 billion, a price-to-earnings ratio of 39.83, a price-to-earnings-growth ratio of 2.78 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company has a fifty day moving average price of $212.41 and a 200 day moving average price of $195.13.

Danaher (NYSE:DHR) last posted its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same period in the previous year, the business posted $0.77 EPS. Danaher’s revenue was up 5.5% on a year-over-year basis. On average, analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio is currently 28.42%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on DHR shares. Guggenheim boosted their target price on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Weiss Ratings upgraded shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research report on Saturday. UBS Group began coverage on shares of Danaher in a report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price target for the company. Finally, Barclays boosted their price objective on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $235.41.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.